检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:李朝战[1] 黄勇[1] 杨慧[1] 王星际[1] 张超[1]
机构地区:[1]山东省枣庄市立医院普外科,山东枣庄277000
出 处:《中国现代普通外科进展》2010年第9期688-690,722,共4页Chinese Journal of Current Advances in General Surgery
摘 要:目的:探讨乳腺癌新辅助化疗的临床效果及其对ER、Survivin和C-erB-2表达的影响。方法:62例可手术乳腺癌采用TE方案新辅助化疗观察客观有效率及新辅助化疗前后ER、Survivin和C-erB-2的表达。结果:新辅助化疗后临床完全缓解(CR)9例,部分缓解(PR)38例,病情稳定(SD)14例,疾病进展(PD)1例。新辅助化疗后Survivin表达明显下降(P<0.05),ER及C-erB-2阳性表达率均低于新辅助化疗前但差异无统计学意义(P>0.05)。Survivin化疗后表达降低者化疗有效率高,Survivin表达升高者化疗有效率低,二者之间有相关性,ER、C-erB-2表达变化与化疗有效率之间无相关性。结论:乳腺癌新辅助化疗可以有效的缩小肿瘤;Survivin在新辅助化疗后表达显著降低,而ER、及C-erB-2的阳性表达降低,但无显著影响。Objective:To investigate the clinical effect of neoadjuvant chemotherapy to breast cancerand the influence to the ER,Survivin and C-erB-2 expression.Methods:sixtytwo patients of operable breast cancer were treated with neoadjuvant chemotherapy TE program.The ER,Survivin and C-erB-2 expression were observated before and after neoadjuvant chemotherapy.Results:Afterneoadjuvant chemotherapy clinical complete remission(CR)in 9 cases,partial remission(PR)in 38 cases,stable disease (SD)in 14 cases,no disease progression (PD)in 1 case.Afterneoadjuvant chemotherapy Survivin expression was significantly decreased (P〈0.05),ER and C-erB-2 positive expression rate were lower with no significant difference (P〉0.05).The efficiency of chemotherapy were low in patients with increased Survivin expression and the efficiency were high in patients with decrsased Survivin expression.There was no significant relation between the ER,C-erB-2 expression and the efficiency of chemotherapy.Conclusion:Neoadjuvant chemotherapy in breast cancer can effectively reduce the tumor;Survivin expression after neoadjuvant chemotherapy depresses significantly and the positive expression of ER and C-erB-2 positive depress with no signficant effect.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.177